Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Boryung Launches 2024 Humans In Space Challenge: Sending Experiments into Orbit

* Boryung to support the launch of space experiments into orbit for selected startups and researchers * Held for the third consecutive year, HIS presents an expanded ecosystem of engagements with NASA, ISS National Lab,MIT, and major space companies * Humans In Space(HIS) will serve as a glo...

2024-05-02 20:00 1740

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...

2024-05-02 07:01 1802

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...

2024-05-01 17:14 1401

135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management

GUANGZHOU, China, May 1, 2024 /PRNewswire/ -- In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from theMedicines, Health Products and Medical Devices secto...

2024-05-01 13:40 1557

135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...

2024-05-01 08:59 1530

Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations

SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...

2024-04-30 23:00 2631

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World

THE HAGUE, Netherlands, April 30, 2024 /PRNewswire/ -- The 12th Microbiome and Probiotics R&D and Business Collaboration Forum was held with great fanfare in The Hague, Netherlands from April 23rd to 24th, 2024. This prestigious conference is a leading event in the probiotics sector, drawing toget...

2024-04-30 21:09 1671

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...

2024-04-30 20:55 1655

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...

2024-04-30 20:16 1642

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...

2024-04-30 19:00 1518

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed...

2024-04-30 19:00 2947

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial result...

2024-04-30 14:30 1536

WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

* The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. * The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas ...

2024-04-30 10:55 1605

Waterdrop Inc. Releases 2023 Annual Report: Sustained Profitability and Impressive Growth in Innovative Businesses

BEIJING, April 29, 2024 /PRNewswire/ -- On April 25, 2024, Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, released its annual report on Form 20-F for the fiscal year ending...

2024-04-30 10:39 3182

Hurom Takes Global Action to Protect Juicer Patents

Protecting Proprietary Technologies and Fostering a Healthy Global Ecosystem SEOUL, South Korea, April 29, 2024 /PRNewswire/ -- Hurom, a pioneer in the development of the slow juicer and a leader in the global market, is stepping up efforts to safeguard patent rights worldwide to protect its prop...

2024-04-29 21:00 1331

Medit launches the revolutionary i900, an intraoral scanning system set to redefine the scanning experience for dental clinics worldwide

* The Medit i900 features cutting-edge technology for smoother, easier scanning, comfortable handling, and improved scan quality SEOUL, South Korea and LONG BEACH, Calif., April 29, 2024 /PRNewswire/ -- Medit (www.medit.com ), a leading provider of dental 3D scanners and ...

2024-04-29 21:00 1597

Medit launches the revolutionary i900, an intraoral scanning system set to redefine the scanning experience for dental clinics worldwide

China Jo-Jo Drugstores Announces $1.53 Million Registered Direct Offering

HANGZHOU, China, April 29, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...

2024-04-29 21:00 2296

CARsgen Submitted Responses to FDA Observations

SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive...

2024-04-29 20:50 1213

Laekna Releases 2023 ESG Report

SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX onJune 29, 2023. Laekna means "to cure, to heal", underscor...

2024-04-29 20:30 1331

Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

CHENGDU, China, April 29, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in t...

2024-04-29 20:00 1430

1 ... 44 45 464748 49 50 ... 283